

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant
Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

**ROYALTY PHARMA
ROYALTY PHARMA PLC**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:

 - (2) Aggregate number of securities to which transaction applies:

 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 - (4) Proposed maximum aggregate value of transaction:

 - (5) Total fee paid:

- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:

 - (2) Form, Schedule or Registration Statement No.:

 - (3) Filing Party:

 - (4) Date Filed:

Your **Vote** Counts!

ROYALTY PHARMA PLC

2021 Annual General Meeting

Vote by June 23, 2021

11:59 PM ET

ROYALTY PHARMA

ROYALTY PHARMA PLC
THE PAVILIONS, BRIDGWATER ROAD
BRISTOL, BS13 8AE
UNITED KINGDOM



D47953-P55674

You invested in ROYALTY PHARMA PLC and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting. **This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 24, 2021.**

Get informed before you vote

View the Notice of Annual General Meeting of Shareholders, Proxy Statement, Annual Report on Form 10-K and U.K. Annual Report and Accounts online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 10, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and
vote without entering a
control number



Vote Virtually at the Meeting*

June 24, 2021
9:00 AM ET

Virtually at:
www.virtualshareholdermeeting.com/RPRX2021

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	Board Recommends
1. Election of Directors Nominees:	
1a. Pablo Legorreta	✓ For
1b. Henry Fernandez	✓ For
1c. Bonnie Bassler	✓ For
1d. Errol De Souza	✓ For
1e. Catherine Engelbert	✓ For
1f. William Ford	✓ For
1g. M. Germano Giuliani	✓ For
1h. Ted Love	✓ For
1i. Gregory Norden	✓ For
1j. Rory Riggs	✓ For
2. A non-binding advisory vote to approve executive compensation.	✓ For
3. A non-binding advisory vote to approve the frequency of future votes on executive compensation.	1 Year
4. Ratify the appointment of Ernst & Young as our independent registered public accounting firm.	✓ For
5. Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2020.	✓ For
6. Approve our U.K. directors' remuneration policy.	✓ For
7. Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the directors' remuneration policy).	✓ For
8. Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.	✓ For
9. Authorize the board of directors to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.	✓ For

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".